GENE ONLINE|News &
Opinion
Blog

Daniel Ojeda

WRITTEN BY Daniel Ojeda

Oculis Raises $50 Million to Push Ophthalmic Portfolio and Expand International Foothold
2021-05-06
Full Approval of Treatment Standard Forces Avrobio to Adjust Fabry Disease Therapy Plans
2021-05-04
Boundless Bio Raises Fresh Capital to Boost extrachromosomal DNA Targeting Therapeutic Efforts
2021-04-30
CRISPR Gene Editing Could Lead to Possible Detrimental Chromosomal Rearrangement
2021-04-25
Targeting KRAS Mutants: Advances in Drugging the “Undruggable”
2021-04-19
T Cells and Cancer: Uncovering the Unknowns
2021-04-16
Recent Advances in CAR T-Cell Therapy Development
2021-04-14
Understanding Cancer Chromosomal Instability: Highlights from the AACR2021 Discovery Science Plenary Session
2021-04-11
Inscripta Raises New Capital, Hits a Sales Milestone the Same Day
2021-04-07
Ionis’ Once-Monthly Treatment for Rare Hereditary Disease Achieves Trial Endpoints
2021-03-31
Human Organoids as a Model for Drug Discovery: Advantages and Main Players
2021-03-30
BMS’s Combo Therapy Involving LAG-3 Drug Impresses in Melanoma Trial
2021-03-27
Merck’s Anti-PD1 Therapy Receives Second FDA Approval for Esophageal Carcinoma
2021-03-25
With $41.9 Million from Oversubscribed Financing Round, XyloCor Sets Sights on Gene Therapy for Heart Disease
2021-03-23
Gilead, Merck Unite to Contest ViiV’s Cabenuva with Long-Acting HIV Therapy
2021-03-16
1 … 3 4 5 6 7 … 9
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top